Skip to main content
Top
Published in: Breast Cancer Research 1/2002

01-07-2002 | Meeting abstract

Invasive cancer

Author: IO Ellis

Published in: Breast Cancer Research | Special Issue 1/2002

Login to get access

Excerpt

Breast screening detects a wide spectrum of breast cancer, ranging from microfocal low-grade ductal carcinoma in situ (DCIS) to large high-grade invasive cancer (Cowan et al., 1991; Klemi et al., 1992; Rajakariar et al., 1995). It has been proposed that detecting in situ cancer, particularly high-grade DCIS, would prevent the development of high-grade invasive cancer (Lampejo et al., 1994; Evans et al., 1997, 2001). It is well recognised that many low-grade, special invasive cancers are identified at screening (Cowan et al., 1991; Klemi et al., 1992; Porter et al., 1999). Such tumours have an excellent prognosis but may be so indolent that they would never have presented clinically or have threatened the life of the patients. It has been proposed alternatively that a proportion of these low-grade invasive tumours might de-differentiate over time into more aggressive, less well differentiated tumours (Tabár et al., 1999), although this was not found in another screening programme (Hakama et al., 1995). Identification and removal of such cancers when they are at a low-grade would avoid such progression. Detection of high-grade invasive cancers when they are small is clearly a means by which screening could reduce breast cancer mortality. In support of this possibility, it was shown in the two-county trial in Sweden that histological grade 3 invasive cancers detected when less than 10 mm have an excellent prognosis (Tabár et al., 1999), while it is widely recognised that large high-grade invasive cancers have a poor prognosis. In addition the presence of vascular invasion and lymph node metastasis, which are associated with development of metastatic disease, are rare in grade 3 tumours <10 mm, grade 2 tumours <10 mm and grade 1 tumours <20 mm, indicating that detecting tumours under a certain size should be beneficial (Evans et al., 2001). …
Metadata
Title
Invasive cancer
Author
IO Ellis
Publication date
01-07-2002
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2002
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr483

Other articles of this Special Issue 1/2002

Breast Cancer Research 1/2002 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine